These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2647388)

  • 21. Inhibition of peptic ulcer relapse by ranitidine and ecabet independently of eradication of Helicobacter pylori: a prospective, controlled study versus ranitidine.
    Koizumi W; Tanabe S; Imaizumi H; Kida M; Ohida M; Koshida Y; Mitomi H; Hosaka Y; Nagaba S; Sasaki T; Higuchi K; Saigenji K
    Hepatogastroenterology; 2003; 50(50):577-81. PubMed ID: 12749277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic approach to peptic ulcer relapse.
    Rodrigo JM; Ponce J
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():131-5. PubMed ID: 2657284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peptic ulcer disease in pregnancy.
    Michaletz-Onody PA
    Gastroenterol Clin North Am; 1992 Dec; 21(4):817-26. PubMed ID: 1478737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aging and upper gastrointestinal disorders.
    Pilotto A
    Best Pract Res Clin Gastroenterol; 2004; 18 Suppl():73-81. PubMed ID: 15588798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of protective drugs in the prevention of ulcer relapse.
    Ota S; Terano A
    J Gastroenterol; 1994 Jul; 29 Suppl 7():139-40. PubMed ID: 7921147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eradication of Helicobacter pylori improves the healing rate and reduces the relapse rate of nonbleeding ulcers in patients with bleeding peptic ulcer.
    Arkkila PE; Seppälä K; Kosunen TU; Haapiainen R; Kivilaakso E; Sipponen P; Mäkinen J; Nuutinen H; Rautelin H; Färkkilä MA
    Am J Gastroenterol; 2003 Oct; 98(10):2149-56. PubMed ID: 14572560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Peptic ulcer disease etiology, diagnosis and treatment].
    Bak-Romaniszyn L; Wojtuń S; Gil J; Płaneta-Małecka I
    Pol Merkur Lekarski; 2004; 17 Suppl 1():128-32. PubMed ID: 15603370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrence of peptic ulcer in uraemic and non-uraemic patients after Helicobacter pylori eradication: a 2-year study.
    Tseng GY; Lin HJ; Fang CT; Yang HB; Tseng GC; Wang PC; Hung TL; Deng YC; Cheng YT; Huang CH
    Aliment Pharmacol Ther; 2007 Sep; 26(6):925-33. PubMed ID: 17767477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maintenance therapy for peptic ulcer disease: an overview of medical treatment.
    Schnell TG
    J Assoc Acad Minor Phys; 1992; 3(4):123-9. PubMed ID: 1392406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of long-term half-dose famotidine therapy on corpus gastritis in peptic ulcer disease.
    Kamada T; Hata J; Kusunoki H; Sugiu K; Ito M; Tanaka S; Kawamura Y; Chayama K; Haruma K
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():99-104. PubMed ID: 15943855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sucralfate and other non-antisecretory agents in the treatment of peptic ulcer disease.
    May B
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():113-6. PubMed ID: 2657280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long term cimetidine therapy for the prevention of recurring peptic ulcer: a multicenter study.
    Rohner HG
    Z Gastroenterol; 1985 Aug; 23(8):403-11. PubMed ID: 3933199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up after eradication of Helicobacter pylori with omeprazole, clarithromycin, and tinidazole (OCT regimen) in a Japanese population.
    Ando T; Minami M; Mizuno T; Watanabe O; Ishiguro K; Ina K; Kusugami K; Nobata K; Nishiwaki T; Tsuzuki T; Shimada M; El-Omar E; Goto H
    Helicobacter; 2005 Oct; 10(5):379-84. PubMed ID: 16181347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Helicobacter pylori and gastroesophageal reflux disease: friends or foes?
    Gisbert JP; Pajares JM; Losa C
    Hepatogastroenterology; 1999; 46(26):1023-9. PubMed ID: 10370661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term course of reflux symptoms following Helicobacter pylori eradication].
    Peitz U; Raps S; Plein K; Leodolter A; Hotz Dagger J; Malfertheiner P
    Dtsch Med Wochenschr; 2004 Mar; 129(13):671-5. PubMed ID: 15026962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. H2-blockers: how safe and how effective?
    Spiro HM
    J Clin Gastroenterol; 1983; 5 Suppl 1():143-7. PubMed ID: 6140282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptic ulcer disease today.
    Yuan Y; Padol IT; Hunt RH
    Nat Clin Pract Gastroenterol Hepatol; 2006 Feb; 3(2):80-9. PubMed ID: 16456574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effectiveness and safety of long-term H2-receptor antagonist maintenance therapy].
    Wormsley KG
    Orv Hetil; 1992 Nov; 133(47):3013-7. PubMed ID: 1359491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.